Literature DB >> 26486298

Behçet's disease patients with multiple sclerosis-like features: discriminative value of Barkhof criteria.

Gulsen Akman-Demir1, Melike Mutlu2, Asli Kiyat-Atamer1, Erkingul Shugaiv2, Murat Kurtuncu3, Ilknur Tugal-Tutkun4, Erdem Tuzun5, Mefkure Eraksoy2, Sara Bahar2.   

Abstract

OBJECTIVES: Behçet's disease (BD) is a systemic auto-inflammatory disorder of unknown cause, which may affect the central nervous system in around 5% of the patients [neuro-BD (NBD)], usually causing large lesions encompassing brainstem, diencephalon and basal ganglia regions. Occasionally NBD patients present with white matter lesions necessitating differential diagnosis from multiple sclerosis (MS). In this study, the efficacy of Barkhof criteria was tested in diagnostic differentiation of NBD and MS.
METHODS: Charts and MRIs of 84 NBD patients were retrospectively evaluated. Clinical and radiological features of NBD patients fulfilling (Barkhof+) and not fulfilling Barkhof criteria (Barkhof-) were compared.
RESULTS: While the Barkhof- patients (n=73) mostly displayed typical large lesions covering brainstem, diencephalon and basal ganglia regions and neurological findings consistent with brainstem involvement, all Barkhof+ (n=11) patients demonstrated MS-like white matter lesions, fulfilled McDonald's criteria and showed reduced frequency of brainstem symptoms and increased frequency of hemiparesis, hemihypesthesia and spinal cord symptoms. Moreover, the Barkhof+ group had more female patients, increased number of attacks, higher rate of oligoclonal band positivity and less patients with cerebrospinal fluid pleocytosis.
CONCLUSIONS: A subgroup of BD patients with neurological complaints displays MS-like lesions, fulfills the clinical and radiological criteria of MS and presents with clinical and laboratory features resembling those of MS rather than NBD. These results suggest that Barkhof+ patients are either an overlapping group between NBD and MS, or they represent MS patients with concomitant systemic findings of BD, rather than NBD. Barkhof criteria appear to be effective in discriminating these patients.

Entities:  

Mesh:

Year:  2015        PMID: 26486298

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  10 in total

1.  Effects of in vivo and in vitro administration of neuro-Behcet's disease IgG.

Authors:  Ece Erdağ; Ceren Şahin; Cem İsmail Küçükali; Sinem Bireller; Melike Küçükerden; Murat Kürtüncü; Recai Türkoğlu; Bedia Cakmakoglu; Erdem Tüzün; Feyza Arıcıoğlu
Journal:  Neurol Sci       Date:  2017-02-21       Impact factor: 3.307

Review 2.  Atypical Pediatric Demyelinating Diseases of the Central Nervous System.

Authors:  Regina M Troxell; Alison Christy
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

Review 3.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

Review 4.  Behçet syndrome: a contemporary view.

Authors:  Hasan Yazici; Emire Seyahi; Gulen Hatemi; Yusuf Yazici
Journal:  Nat Rev Rheumatol       Date:  2018-01-03       Impact factor: 20.543

5.  Neurobehçet, multiple sclerosis or overlap syndrome? A case report.

Authors:  Vittorio Mantero; Andrea Rigamonti; Anna Fiumani; Luisa De Toni Franceschini; Ugo Pozzetti; Roberto Balgera; Andrea Salmaggi
Journal:  Neurol Sci       Date:  2018-04-26       Impact factor: 3.307

6.  Impact of Neuro-Behçet Disease Immunoglobulin G on Neuronal Apoptosis.

Authors:  Murat Giriş; Sinem Bireller; Cem İsmail Küçükali; Haşmet Hanağasi; Sevgin Değirmencioğlu; Erdem Tüzün
Journal:  Noro Psikiyatr Ars       Date:  2016-12-08       Impact factor: 1.339

7.  CSF/serum matrix metallopeptidase-9 ratio discriminates neuro Behçet from multiple sclerosis.

Authors:  Alessandra Aldinucci; Elena Bonechi; Tiziana Biagioli; Anna M Repice; Mario M D'Elios; Lorenzo Emmi; Giacomo Emmi; Elena Silvestri; Alessandro Barilaro; Clara Ballerini
Journal:  Ann Clin Transl Neurol       Date:  2018-03-10       Impact factor: 4.511

8.  Characteristics of optic neuropathy in Behçet disease.

Authors:  Gülden Akdal; Hülya Ertaşoğlu Toydemir; Ali Osman Saatci; Uğur Uygunoğlu; Burcu Altunrende; Sabahattin Saip; Aylin Yaman; Pembe Keskinoğlu; Suzan Güven Yilmaz; Neşe Çelebisoy; Meltem Söylev Bajin; Aksel Siva; Gülşen Akman-Demir
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-08-10

9.  Neuroradiological differentiation of white matter lesions in patients with multiple sclerosis and Fabry disease.

Authors:  Jakob Rath; Olivia Foesleitner; Lukas Haider; Hubert Bickel; Fritz Leutmezer; Stephan Polanec; Michael A Arnoldner; Gere Sunder-Plassmann; Daniela Prayer; Thomas Berger; Paulus Rommer; Gregor Kasprian
Journal:  Orphanet J Rare Dis       Date:  2022-02-05       Impact factor: 4.123

10.  The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis.

Authors:  Tilman Hottenrott; Rick Dersch; Benjamin Berger; Dominique Endres; Daniela Huzly; Jens Thiel; Sebastian Rauer; Oliver Stich; Ulrich Salzer; Nils Venhoff
Journal:  BMC Neurol       Date:  2018-01-31       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.